
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Author(s) -
Danielle Brazel,
Shan Zhang,
Misako Nagasaka
Publication year - 2022
Publication title -
lung cancer
Language(s) - English
Resource type - Journals
ISSN - 1179-2728
DOI - 10.2147/lctt.s360574
Subject(s) - medicine , tolerability , exon , cancer research , lung cancer , clinical trial , receptor tyrosine kinase , oncology , tyrosine kinase inhibitor , tyrosine kinase , clinical practice , mutation , bioinformatics , cancer , gene , receptor , adverse effect , genetics , family medicine , biology